COLL Collegium Pharmaceutical Inc.

Collegium to Report Second Quarter 2022 Financial Results on August 4, 2022

Collegium to Report Second Quarter 2022 Financial Results on August 4, 2022

STOUGHTON, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that it will report second quarter 2022 financial results after the market closes on Thursday, August 4, 2022. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET.

Conference Call Information 

To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q2 2022 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: . The webcast will be available for replay on the Company’s website approximately two hours after the event.

About Collegium Pharmaceutical, Inc.

Collegium is a diversified, specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at .

Contact:

Alex Dasalla

Head of Investor Relations



EN
21/07/2022

Underlying

COLLCollegium Pharmaceutical Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Collegium Pharmaceutical Inc.

 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Report Fourth Quarter and Full-Year 2025 Financial Result...

Collegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026 STOUGHTON, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that it will report fourth quarter and full-year 2025 financial results before the market opens on Thursday, February 26, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q4 ...

February 12, 2026 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Present Four Real-World Data Posters at APSARD 2026 Annua...

Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference STOUGHTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) today announced it will have four poster presentations highlighting real-world data from its ADHD product, Jornay PM (methylphenidate HCl), a central nervous system (CNS) stimulant indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in people 6 years of age and older and developed using a novel delayed-release extended-release delivery platform, at the American Professional Society of ADHD and Related Disorders (A...

January 15, 2026 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Provides 2026 Financial Guidance and Business Update

Collegium Provides 2026 Financial Guidance and Business Update – Product Revenues, Net Expected in the Range of $805 Million to $825 Million – – Jornay PM® Net Revenue Expected in the Range of $190 Million to $200 Million – – Adjusted EBITDA* Expected in the Range of $455 Million to $475 Million – STOUGHTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced its 2026 full-year financial guidance and provided a business update. “2025 was a year of record growth for Collegium and we are excited to begin 2026 with significant momentum ...

January 8, 2026 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Announces the Closing of $980 Million Syndicated Credit Faci...

Collegium Announces the Closing of $980 Million Syndicated Credit Facility Five-Year Financing with Favorable Terms that Significantly Reduce Interest Rate STOUGHTON, Mass., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced the closing of its inaugural syndicated credit facility. The new aggregate $980 million credit facility will mature in 2030 and consists of a $580 million initial Term Loan, $300 million Delayed Draw Term Loan, and $100 million revolving credit facility (collectively the “Credit Facility”). The initial Term Loan was used...

December 30, 2025 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Participate in Upcoming Investor Conferences

Collegium to Participate in Upcoming Investor Conferences STOUGHTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: Jefferies London Healthcare ConferencePresentation Date and Time: Wednesday, November 19, 2025, at 8:00 a.m. GMTLondon, UK The presentation will be webcast live and can be accessed from the Investors section of the Company's website: . A replay of the webcast will be archived on the Company's website for 90 days following the presentation. Piper Sandler 37th Annual Health...

November 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch